Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

2 months ago 9
Read Entire Article
  1. Homepage
  2. Finance
  3. Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related

JPMorgan cuts Rocket Pharmaceuticals stock rating to neutral

JPMorgan cuts Rocket Pharmaceuticals stock rating to neutral...

32 minutes ago 0
Musk opposed Abu Dhabi AI data center deal that he thought favors Altman, says WSJ

Musk opposed Abu Dhabi AI data center deal that he thought f...

32 minutes ago 0
Belden Inc. holds annual stockholder meeting

Belden Inc. holds annual stockholder meeting

32 minutes ago 0

Trending

1. commuted sentence
2. nava tennis
3. rhode
4. malo gusto
5. salesforce stock
6. elf stock
7. crm stock
8. otega oweh
9. snps stock
10. angel martinez

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

4 months ago 219
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

4 months ago 135
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

2 months ago 135
TOUS les JOURS Opens in Henderson!

TOUS les JOURS Opens in Henderson!

4 months ago 103
Sole mates: Find the perfect shoes for your fitness journey

Sole mates: Find the perfect shoes for your fitness journey

4 months ago 98
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved